Hematology Weekly News – June 16th 2025 🔬🩸 Hematology Updates: Myeloma Trials, AML Response Breakthroughs & First-in-Canada Therapies From next-gen triplet regimens in AML and continuous low-dose […] The post Hematology Weekly News – June 16th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Hematology Weekly News – June 16th 2025 #News #AML #Bleximenib #Fabhalta #hematology Comment below!

Hematology Weekly News – June 16th 2025 🔬🩸 Hematology Updates: Myeloma Trials, AML Response Breakthroughs & First-in-Canada Therapies From next-gen triplet regimens in AML and continuous low-dose […] The post Hematology Weekly News – June 16th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Hematology Weekly News – June 16th 2025 #News #AML #Bleximenib #Fabhalta #hematology Comment below!

Hematology Weekly News – June 16th 2025 🔬🩸 Hematology Updates: Myeloma Trials, AML Response Breakthroughs & First-in-Canada Therapies From next-gen triplet regimens in AML and continuous low-dose […] The post Hematology Weekly News – June 16th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Hematology Weekly News – June 16th 2025 #News #AML #Bleximenib #Fabhalta #hematology Comment below!

FABHALTA Revolutionizes Complement Inhibitor Market with Oral Administration and Efficacy FABHALTA, an oral complement factor B inhibitor, promises to transform treatments for PNH and IgAN, addressing critical medical needs.

FABHALTA Revolutionizes Complement Inhibitor Market with Oral Administration and Efficacy #United_States #Las_Vegas #Novartis #Fabhalta #iptacopan

Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis Novartis’ kidney disease troika keeps marching forward. | Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts spotted several shor...

What a great time to be in the nephrology space
C3GN now has a therapy
👏🏻 👏🏻 👏🏻
Hi #Iptacopan #Fabhalta

www.fiercepharma.com/pharma/novar...

FDA Approves New Treatments and Medical Devices in March 2025 Roundup The FDA made significant approvals and announcements in March 2025, including a new drug for a rare kidney disease and device innovations.

FDA Approves New Treatments and Medical Devices in March 2025 Roundup #United_States #FDA #Silver_Spring #Fabhalta #C3G

Novartis Secures Third FDA Approval for Fabhalta, Transforming C3G Treatment Landscape Novartis receives FDA approval for oral Fabhalta, the first oral treatment for C3 glomerulopathy, significantly improving options for patients with this rare kidney disease.

Novartis Secures Third FDA Approval for Fabhalta, Transforming C3G Treatment Landscape #USA #Novartis #East_Hanover #Fabhalta #C3G

Max Foundation Partners with Novartis to Improve Access to Innovative PNH Treatment in Low-Income Countries The Max Foundation expands its collaboration with Novartis to provide humanitarian access to Fabhalta® for treating PNH in underserved regions.

Max Foundation Partners with Novartis to Improve Access to Innovative PNH Treatment in Low-Income Countries #USA #Seattle #Novartis #Max_Foundation #Fabhalta